Mankind Pharma (BOM:543904) Long-Term Debt: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543904 Mankind Pharma Ltd BOM:543904
91 GF Score
Price ₹2,399.00
GF Value ₹2,964.25
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Mankind Pharma Long-Term Debt?

Mankind Pharma BOM:543904 +0.49% 91 Long-Term Debt is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:543904 with a GF Score™ of 91/100 and a GF Value™ of ₹2,964.25 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Mankind Pharma's Long-Term Debt for the quarter that ended in Jun. 2026 was ₹0 Mil.

Mankind Pharma's quarterly Long-Term Debt increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹28,212 Mil) but then declined from Mar. 2026 (₹28,212 Mil) to Jun. 2026 (₹0 Mil).

Mankind Pharma's annual Long-Term Debt increased from Mar. 2024 (₹249 Mil) to Mar. 2025 (₹55,262 Mil) but then declined from Mar. 2025 (₹55,262 Mil) to Mar. 2026 (₹28,212 Mil).

Mankind Pharma  (BOM:543904) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Mankind Pharma Long-Term Debt Related Terms

Mankind Pharma Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Mankind Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mankind Pharma Long-Term Debt Chart

Mankind Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial 491.94 231.47 248.70 55,261.90 28,212.30

Mankind Pharma Quarterly Data
Mar20 Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 41,658.10 0.00 28,212.30 0.00
BOM:543904
91GF Score
Mankind Pharma Ltd BOM:543904
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹0 Mil mean?
Mankind Pharma (BOM:543904) has a Long-Term Debt of ₹0 Mil as of Jun. 2026.
Is Mankind Pharma's Long-Term Debt too high?
Mankind Pharma's current Long-Term Debt is ₹0 Mil. Overall, Mankind Pharma has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mankind Pharma's Long-Term Debt compare to ZTS?
Mankind Pharma's Long-Term Debt of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Mankind Pharma's current Long-Term Debt is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mankind Pharma stock overvalued right now?
Based on GuruFocus' analysis, Mankind Pharma (BOM:543904) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,964.25, compared to a current price of ₹2,399.00 — trading 19.1% below its estimated fair value. The current Long-Term Debt is ₹0 Mil. Mankind Pharma's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Mankind Pharma (BOM:543904), the current Long-Term Debt is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mankind Pharma (BOM:543904) Overvalued in 2026?

Based on GuruFocus' analysis, Mankind Pharma stock appears to be undervalued. The current stock price of ₹2,399.00 is trading 19.1% below its estimated GF Value™ of ₹2,964.25. GuruFocus considers Mankind Pharma to be Modestly Undervalued.

Key valuation signals for BOM:543904:

  • Long-Term Debt: ₹0 Mil
  • GF Value™: ₹2,964.25 vs. price of ₹2,399.00 (19.1% below fair value)
  • GF Score™: 91/100 with 3 warning signs

No single metric tells the full story. See the BOM:543904 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mankind Pharma Business Description

Other Exchanges MANKIND:India
Address 262, Okhla Industrial Estate, Phase-III, New Delhi, IND, 110020
Mankind Pharma Ltd is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors providing products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News, Gas-O-Fast, AcneStar and HealthOK. Geographically, the company derives a majority of its revenue from the sale of pharmaceutical products in India and the rest from its customers located outside India.
91GF Score

Get the complete analysis for BOM:543904

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,399.00
Price
₹2,964.25
GF Value